(Communicated)
(CercleFinance.com) – GSK reports positive results from the pivotal Phase III EAGLE-2 and EAGLE-3 trials for gepotidacin, an investigational oral antibiotic with a novel mechanism of action for uncomplicated UTIs in adult and adolescent women.
These trials met the primary endpoint of non-inferiority to nitrofurantoin, with EAGLE-3 even demonstrating statistical superiority. Full results will be submitted to a peer-reviewed scientific journal later this year.
Their presentation at the ECCMID Congress in Copenhagen follows the decision to prematurely stop these two pivotal efficacy trials following a recommendation from the independent data monitoring board in November. 2022.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
